<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880618</url>
  </required_header>
  <id_info>
    <org_study_id>360049-001</org_study_id>
    <nct_id>NCT02880618</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction</brief_title>
  <acronym>HFrEF</acronym>
  <official_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with
      the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the
      CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary:

      The CVRx BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction (HFrEF) Registry
      will be performed with subjects who have been recently implanted with the BAROSTIM NEO System
      in accordance with CE-Mark approved criteria for heart failure. Subjects must be enrolled
      within 30 days from implant. Up to 500 subjects will be enrolled at up to 50 sites. Data
      should be obtained from standard of care measurements taken prior to implant, at
      enrollment/baseline, and at 3, 6, and 12 months after the device was implanted, at which time
      each subject will be exited from the registry.

      Eligibility:

      Subjects can be included in the Heart Failure with Reduced Ejection Fraction Registry if they
      were implanted in the past 30 days and meet the CE-Mark approved indications, and are not
      contraindicated, for the BAROSTIM NEO System in the treatment of heart failure. The BAROSTIM
      NEO System is indicated for subjects with heart failure, defined as New York Heart
      Association (NYHA) functional Class III and left ventricular ejection fraction (LVEF) ≤ 35%
      despite being treated with the appropriate heart failure guideline directed therapy.

      The contraindications are:

        -  Bilateral carotid bifurcations located above the level of the mandible

        -  Baroreflex failure or autonomic neuropathy

        -  Uncontrolled, symptomatic cardiac bradyarrhythmias

        -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to
           be greater than 50%

        -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic
           evaluation

      Objectives:

      To describe change in the following measures at 3, 6 and 12 months compared to pre-implant
      baseline:

        -  New York Heart Association (NYHA) Class

        -  Six Minute Hall Walk

        -  Echocardiogram measures

        -  Biomarkers (e.g. NT-pro BNP, eGFR, Troponin HsT, Cystatin C).

      Evaluate health care utilization over follow-up, such as heart failure hospitalizations.

      Describe device programming and utilization
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change in New York Heart Association Functional Classification at 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>To demonstrate that that treatment with BAROSTIM NEO improves New York Heart Association classification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Six Minute Hall Walk from Baseline to 6 months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>To demonstrate that that treatment with BAROSTIM NEO improves six-minute hall walk performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Mass Index Change from Baseline to 6 Months Post-Implant</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>To demonstrate that that treatment with BAROSTIM NEO reduces left ventricular mass index.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Biomarkers from Baseline to 6 months Post-Implant (e.g. NT-pro BNP, eGFR, Troponin HsT, Cystatin C)</measure>
    <time_frame>Baseline, 6 months post-implant</time_frame>
    <description>To demonstrate that that treatment with BAROSTIM NEO improves biomarker results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Hospitalizations over Follow-Up</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>To demonstrate that that treatment with BAROSTIM NEO reduces hospitalizations.</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barostim Neo™ System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects can be included in the Heart Failure with Reduced Ejection Fraction Registry if
        they were implanted in the past 30 days and meet the CE-Mark approved indications, and are
        not contraindicated, for the BAROSTIM NEO System in the treatment of heart failure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has heart failure, defined as New York Heart Association (NYHA) functional
             Class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated
             with the appropriate heart failure guideline directed therapy

          -  Subject has been implanted with the BAROSTIM NEO System in the past 30 days

          -  Subject has signed an Ethics Committee approved informed consent form

        Exclusion Criteria:

          -  Bilateral carotid bifurcations located above the level of the mandible

          -  Baroreflex failure or autonomic neuropathy

          -  Uncontrolled, symptomatic cardiac bradyarrhythmias

          -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to
             be greater than 50%

          -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Müller-Ehmsen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asklepios Klinik Altona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liz Galle</last_name>
    <phone>763-416-2876</phone>
    <email>lgalle@cvrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum Bad Oyenhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Wellmann</last_name>
      <phone>+49 5721 973327</phone>
      <email>Bwellmann@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Klaus-Jürgen Gutleben</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin Charité &amp; Deutschen Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum am Küchwald GmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lippe Klinikum</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden - Interventionelle Kardiologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Hellwig</last_name>
      <phone>+49 641 985 42632</phone>
      <email>gabriele.hellwig@med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Jörn Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Biegler</last_name>
      <phone>+49 551-39-10880</phone>
      <email>cbiegler@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Marco Schroeter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albertinen-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Jürgens</last_name>
      <phone>+49 511 532 6054</phone>
      <email>juergens.antje@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Christian Veltmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologie im Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln Herzzentrum</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herzentrum Lahr</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leipzig St. Georg</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Reichelt</last_name>
      <phone>+49 341 909-4561</phone>
      <email>susanne.reichelt@sanktgeorg.de</email>
    </contact>
    <investigator>
      <last_name>Norbert Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus Siegen</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus &amp; MVZ Maria-Hilf Stadtlohn GmbH</name>
      <address>
        <city>Stadtlohn</city>
        <zip>48970</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Tuttlingen</name>
      <address>
        <city>Tuttlingen</city>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Weber</last_name>
      <phone>+49 7461 97 1415</phone>
      <email>i.weber@klinikum-tut.de</email>
    </contact>
    <investigator>
      <last_name>Michael Kotzerke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione di Ricerca e Cura &quot;Giovanni Paolo II&quot;</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.barostimtherapy.com/</url>
    <description>BAROSTIM THERAPY</description>
  </link>
  <reference>
    <citation>Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015 Jun;3(6):487-496. doi: 10.1016/j.jchf.2015.02.006. Epub 2015 May 14.</citation>
    <PMID>25982108</PMID>
  </reference>
  <reference>
    <citation>Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail. 2015 Oct;17(10):1066-74. doi: 10.1002/ejhf.299. Epub 2015 Jun 10.</citation>
    <PMID>26011593</PMID>
  </reference>
  <reference>
    <citation>Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014 Sep;16(9):977-83. doi: 10.1002/ejhf.138. Epub 2014 Jul 28.</citation>
    <PMID>25067799</PMID>
  </reference>
  <reference>
    <citation>Gronda E, Seravalle G, Trevano FQ, Costantino G, Casini A, Alsheraei A, Lovett EG, Vanoli E, Mancia G, Grassi G. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens. 2015 Aug;33(8):1704-8. doi: 10.1097/HJH.0000000000000603.</citation>
    <PMID>26132760</PMID>
  </reference>
  <reference>
    <citation>Weaver FA, Abraham WT, Little WC, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Madershahian N, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Zile MR. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. Semin Thorac Cardiovasc Surg. 2016 Summer;28(2):320-328. doi: 10.1053/j.semtcvs.2016.04.017. Epub 2016 Jun 2.</citation>
    <PMID>28043438</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

